https://safirsoft.com Womp, Womp: The effectiveness of Thor-inspired Quid Merck tablets disappears, alarming experts
FDA advisors voted 13-10 in favor of the license given the small risks and benefits, and they backed Merck. For use against severe COVID-19 disease.
The Food and Drug Administration's Antimicrobial Advisory Committee (AMDAC) met in an all-day meeting Tuesday to assess the drug's small risks and benefits and the limited data available. Recent analysis shows that the pill is only 30% effective in preventing hospitalization from COVID-19 and death in people at high risk of serious illness. Meanwhile, the drug has a troubling potential for mutagenicity, leading consultants to consider whether or not it should be given to pregnant women. This is the medicine. , which initially promised to be an easy-to-use oral drug for effective prevention of COVID-19. "Our expectation from the lab studies, now with this data, is that molonoperavir is properly named [something] ... it's a hammer against SARS-CoV-2, no matter what it is," Merck said. Dean told me last month.

At the time, Merck issued a press release showing that the antiviral pill increases the risk of hospitalization and death from COVID-19 by nearly 50% in infected people. With a high risk of severe disease, the results were obtained from a temporary analysis of 762 people who were monitored about a month after a positive test result. In the placebo group, Merck reported that 53 of the 377 people were hospitalized with Covid-19 and eight died. Of the 386 people who received the drug, only 28 were hospitalized and none died. Comparing the two groups, the hospitalization and death rate in the placebo group was 14.1 percent, while it was only 7.3 percent in the molnopiravir group.

Collected. This group of people, the profit of Molnopiravir has disappeared. Of the 322 people in the placebo group, 15 were hospitalized and one died. That is, the hospitalization and death rate with the placebo was about 4.7%. Of the 324 people who received molopiravir, 20 were hospitalized and 1 died. The hospitalization and death rate is 6.2 percent, which is slightly higher than the placebo group. Announcement

Difficult Decisions

It has also met. It concluded that generally, molonoperavir is 30% effective in preventing hospitalization and death. Of the 699 people who received placebo, 68 were hospitalized and 9 died. Of the 710 people who received molonoperavir, 48 were hospitalized and 1 died. The hospitalization and mortality rate in the placebo group was 9.7% compared to 6.8% in the molonopiravir group, indicating a 3% reduction in absolute risk and a 30% reduction in relative risks. FDA panel members described the efficacy data as “very good” and “at best.” Although there were no safety concerns about any of the trial data, FDA reviewers were unaware. Potential mutagenic effects Molnopiravir destroys SARS-CoV-2 by acting as a decoy agent for the virus's genetic code. But, with this strategy, there is also the possibility that it could disrupt the human genetic code. Members of AMDAC strongly felt that Merck had not adequately monitored immunity to understand the risk of mutations in individuals, especially pregnant women. Reducing deaths from Covid-19 and the marginal benefits and risks offered by this particular drug. In closing remarks, several advisors said their final vote was a difficult decision and called for more statements. Some of those who voted in favor expressed limited scenarios in which they could support drug use, that is, for high-risk, non-pregnant, unvaccinated individuals who understand the risks of the drug and are sure to take it as prescribed.

After a close vote and many concerns, the Food and Drug Administration will now decide whether to issue an emergency use authorization for mulnopiravir. The regulator tends to follow the advice of its advisory committees.

In addition to molopiravir, the Food and Drug Administration will also consider Pfizer's antiviral birth control pill, which the company says is 89 percent safe for hospitalization. inactive. -19. Pfizer notes that the drug has no mutagenic risk.



https://safirsoft.com The journey of the James Webb Space Telescope to its final orbit was successful

The journey of the James Webb Space Telescope to its final orbit was successful

With the precise deployment of the James Webb Space Telescope in its final orbit, the Lagrangian point halo orbit is the last step in a month-long jou...


https://safirsoft.com The iPhone 15 Pro may come with a display made by the Chinese company BOE

The iPhone 15 Pro may come with a display made by the Chinese company BOE

There have been many rumors in recent months about Apple trying to discard Samsung-made displays. In 2020, there were some reports of the use of scree...

https://safirsoft.com The 9000 Density chipset is likely to make its way into Samsung's Galaxy A series handsets

The 9000 Density chipset is likely to make its way into Samsung's Galaxy A series handsets

Samsung Galaxy S22 series phones will be introduced soon along with Exynos 2200 and Snapdragon 8 generation 1 chips. Meanwhile, it seems that Samsung ...


https://safirsoft.com 8 main reasons for the failure of entrepreneurship and investments

8 main reasons for the failure of entrepreneurship and investments

Entrepreneurship is a really complex subject. If entrepreneurs do not always do their best, they are more likely to fail. Research has shown that more...